A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

NCT04752540 PHASE1 COMPLETED

A single oral dose study to investigate the PK and safety of olorofim in mild and moderately hepatically impaired subjects compared to subjects with normal hepatic function.

Details

Lead sponsor	F2G Biotech GmbH
Phase	PHASE1
Status	COMPLETED
Enrolment	32
Start date	Fri Jul 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Oct 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatic Impairment

Interventions

• Olorofim

Countries

United States